Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human study of ANN-002 in treatment of hereditary angioedema

Trial Profile

A first-in-human study of ANN-002 in treatment of hereditary angioedema

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 26 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADVM 053 (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 08 Nov 2018 According to an Adverum Biotechnologies media release, the company will not submit an IND application, as it plans to conduct additional preclinical studies to determine the best gene therapy candidate to advance for the rare disease programs.
    • 01 Nov 2018 According to an Adverum Biotechnologies media release, the company will not submit an IND application for ADVM-053 for the treatment of hereditary angioedema (HAE) in the fourth quarter of 2018.
    • 08 Nov 2017 According to an Adverum Biotechnologies media release, the Company also plans to file an IND application with the FDA in the second half of 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top